Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review.
Adipose Tissue
/ metabolism
Adiposity
Angiotensin-Converting Enzyme Inhibitors
Exercise
Exercise Therapy
Female
Gastrointestinal Microbiome
Ghrelin
/ antagonists & inhibitors
Humans
Male
Myostatin
/ antagonists & inhibitors
Obesity
/ classification
Osteoporosis
Prevalence
Receptors, Androgen
/ metabolism
Risk Factors
Sarcopenia
/ classification
Subcutaneous Fat
/ metabolism
Testosterone
/ metabolism
Treatment Outcome
Obesity
Osteoporosis
Osteosarcopenia
Sarcopenia
Sarcopenic obesity
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
26
09
2018
accepted:
02
05
2019
pubmed:
18
5
2019
medline:
30
9
2020
entrez:
18
5
2019
Statut:
ppublish
Résumé
The co-existence of impaired bone health (osteopenia/osteoporosis), reduced muscle mass and strength (sarcopenia), and increased adiposity (obesity) in middle-aged and older people has been identified in recent studies, leading to a proposal for the existence of "osteosarcopenic obesity" as a distinct entity. Evidence for the pathophysiological overlap of these conditions is mounting, although a causal relationship is yet to be established. Each component condition occurs frequently with increasing age, and with shared risk factors in many instances, thus, an overlap of these three conditions is not surprising. However, whether the concurrent existence of sarcopenia, osteoporosis and obesity leads to an increased risk of adverse musculoskeletal outcomes and mortality above and beyond the risks associated with the sum of the component parts remains to be proven and is a question of research interest. In this article, we review evidence for the existence of osteosarcopenic obesity including the current operational definition of osteosarcopenic obesity, prevalence, pathophysiology, outcomes and exploratory approaches to the management of components. We conclude that, there is insufficient evidence to support a discrete clinical entity of osteosarcopenic obesity at this time. To expand knowledge and understanding in this area, there is a need for consensus on a definition of osteosarcopenic obesity which will allow for identification, further epidemiological studies and comparisons between studies. Additionally, studies should assess whether the clinical outcomes associated with osteosarcopenic obesity are worse than the mere addition of those linked with its components. This will help to determine whether defining a person as having this triad will eventually result in a more effective treatment than addressing each of the three conditions separately.
Identifiants
pubmed: 31098729
doi: 10.1007/s00223-019-00561-w
pii: 10.1007/s00223-019-00561-w
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Ghrelin
0
Myostatin
0
Receptors, Androgen
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-124Subventions
Organisme : Versus Arthritis
ID : 19583
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P020941/1
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn